Increasing the quality of clinical trials in oncology: An important challenge;Améliorer la qualité des essais thérapeutiques en oncologie: Un défi important

Bulletin du Cancer

Volumn 90, Issue 10, 2003, Pages 919-923

  Kramar, Andrew ^a   Kachmar, Taras ^b   Hannoun Lévi, Jean Michel ^c  

^a CENTRE VAL D AURELLE   (France)

^b Centre Régional d'Oncologie   (Ukraine)

^c CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Clinical trial; Interim analyse; Methodological biase; Quality

Indexed keywords

ARTICLE; MEDICAL LITERATURE; ONCOLOGY; QUALITY CONTROL; STATISTICAL ANALYSIS; TREATMENT PLANNING;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; HUMANS; MEDICAL ONCOLOGY; QUALITY CONTROL;

EID: 0344394247     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hill C. Il faut changer la façon de faire les essais randomisés en cancérologie. Bull Cancer 2002 ; 89 : 823-5.
2. Nag S, Beyer D, Friedland J, Grimm P, Nach R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999 ; 44 : 789-99.
3. Baselga J, Hammond LA. HER-targeted tyrosine-kinase inhibitors. Oncology 2002 ; 63 Suppl 1 : 6-16.
4. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor recepror tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002 ; 20 : 4292-302.
5. ICH E10. Choice of control group in clinical trials. CPMP/ICH/364/96, 2000. (www.ich.org)
6. Hill C, Pignon JP. Apport et limites des méta-analyses d'essais thérapeutiques en oncologie. Bull Cancer 1999 ; 86 : 259-64.
7. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncology 2001 ; 2 : 475-82.
8. Sancho-Garnier H. A la recherche du p inférieur ou égal à 5 %. Bull Cancer 1998 ; 85 : 1067-9.
9. Buyse M, George SL, Evans S, Geller N, Ranstam J, Scherrer B, et al. pour le comité fraude de I'ISCB. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med 1999 ; 18 : 3435-51.
10. Maraninchi D. Recherche (clinique) en cancérologie : quels enjeux pour les années 2000? Bull Cancer 1999 ; 86 : 526-8.
11. ICH E9. Statistical principles for clinical trials. CPMP/ICH/363/96, 1998.
12. Kramar A, Potvin D, Hill C. Plans expérimentaux pour l'inclusion de patienrs dans les essais de phase II. Rev Epidémiol Santé Publique 1996 ; 44 : 364-71.
13. Mehra CR, Tsiatis AA. Flexible sample size considerations using information-based inrerim monitoring. Drug Information Journal, December 2001.
14. Mehta C. EaSt 2000. Cytel Software Corporation, Cambridge, MA, USA 2000.
15. Rosner GL, Tsiatis AA. The impact that group sequential tests would have made on ECOG clinical trials. Stat Med 1989 ; 8 : 505-16.
16. Fleming TR. Data monitoring committees and capturing relevant information of high quality. Stat Med 1993 ; 12 : 565-70 ; discussion 571-3.
17. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients wirh a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001 ; 92 : 2639-47.
18. Balducci L, Lyman GH. Cancer in the elderly. Epidemiologic and clinical implications. Clin Geriatr Med 1997 ; 13 : 1-14.
19. Balducci L, Extermann M, Catreca I. Management of breast cancer in the older woman. Cancer Control 2001 ; 8 : 431-4.
20. ICH E11. Clinical investigations of medicinal products in the pediatric population CPMP/ICH/2711/99, 2000.
21. Zelen M, Gelman R, Assessment of adjuvant trials in breast cancer. NCI Monogr 1986 ; 1 : 11-7.
22. ICH E7. Studies in support of special populatons: geriatrics. CPMP/ICH/379/95, 1993.
23. Vicini FA, Baglan KL, Kestin LL, et al. Accelerated treatment of breast cancer. J Clin Oncol 2001 ; 19 : 1993-2001.
24. Veronesi U, Orecchia R, Luini A, et al. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers chat are conservatively treated. Eur J Cancer 2001 ; 37 : 2178-83.
25. Buyse M, Piedbois P, Piedbois Y, Carlson RW. Meta-analysis: methods, strengths, and weaknesses. Oncology 2000 ; 14 : 437-43 ; discussion 444, 447.
26. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002 ; 21 : 589-624.
27. Murray GD. Promoting good research practice. Stat Methods Med Res 2000; 9: 17-24.